Edoxaban: Impact on routine and specific coagulation assays: A practical laboratory guide
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Summary: Assessment of plasma concentration/effect of edoxaban may be useful in some situations. Also, clinicians need to know how routine coagulation assays are influenced. It was our aim to determine coagulation tests useful for the assessment of edoxaban’s pharmacodynamics and provide recommendations for the interpretation of haemostasis diagnostic tests. Edoxaban was spiked at concentrations ranging from 0 to 1,000 ng/ml in platelet-poor plasma which covers the on-therapy range (from ± 25 ng/ml at Ctrough to ± 170 ng/ml at Cmax). aPTT, PT, dRVVT, chromogenic anti-Xa assays, TGA and a large panel of haemostasis diagnostic tests were performed using several reagents. A concentration-dependent prolongation of aPTT, PT and dRVVT was observed. The effect was dependent on the reagents. FXa chromogenic assays showed high sensitivity and a linear correlation depending on the methodology. TGA may be useful to assess the pharmacodynamics of edoxaban but its turnaround time and the lack of standardisation are limitations. Edoxaban impairs the assessment of lupus anticoagulant, protein S (clotting method), APC-R, antithrombin (FXa-based assay) and measurement of clotting factor activity. Immunological assays and assays acting below the FXa are not influenced by edoxaban. In conclusion, some PT reagents could be used to estimate edoxaban activity. Chromogenic anti-Xa assays are required to assess the plasma concentration. TGA may be useful but requires standardisation. In case of thrombophilia or in the exploration of a haemorrhagic event, immunological assays should be recommended, when applicable. Standardisation of the time between the last intake and the sampling is mandatory to provide a proper assessment of the result. Supplementary Material to this article is available online at www.thrombosis-online.com.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
The Hokusai-VTE Investigators (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306638 · Cited by 1,869 · cited 1×
“doses were halved in case of concomitant treatment with potent P-gp inhibitors, in case of creatinine clearance (CrCl) of 30 to 50 ml/minute [min] or in case of a body weight of 60 kg or less) (1, 2).”
BackgroundRuff, C. T., Giugliano, R. P., Braunwald, E., Morrow, D. A., Murphy, S. A., Kuder, J. F., Deenadayalu, N., Jarolim, P., Betcher, J., Shi, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61943-7 · Cited by 405 · cited 3×
“This reveals that even if the majority of the patients are likely to receive a “normal” dose regimen, some dose adaptation can be proposed based on the solely clinical characteristics (4).”
BackgroundRecent Guidelines and Recommendations for Laboratory Detection of Lupus Anticoagulants
Moore, G. (2014) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0033-1364185 · Cited by 149
Cited by
Tomaselli, G. F., Mahaffey, K. W., Cuker, A., Dobesh, P. P., Doherty, J. U., Eikelboom, J. W., Florido, R., Gluckman, T. J., Hucker, W. J., Mehran, R., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.053 · Cited by 397
Gosselin, R., Adcock, D., Bates, S., Douxfils, J., Favaloro, E., Gouin-Thibault, I., Guillermo, C., Kawai, Y., Lindhoff-Last, E., & Kitchen, S. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1627480 · Cited by 392
Self-citationDouxfils, J., Ageno, W., Samama, C. ‐., Lessire, S., ten Cate, H., Verhamme, P., Dogné, J. ‐., & Mullier, F. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13912 · Cited by 382
Self-citationFavresse, J., Lardinois, B., Sabor, L., Devalet, B., Vandepapeliere, J., Braibant, M., Lessire, S., Chatelain, B., Jacqmin, H., Douxfils, J., et al. (2018) · TH Open · doi:10.1055/s-0038-1657785 · Cited by 73
Self-citationHillarp, A., Strandberg, K., Gustafsson, K. M., & Lindahl, T. L. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14829 · Cited by 23
Metadata
- Authors
- Chatelain, B., Chatelain, C., Douxfils, J., Dogné, J.-M., & Mullier, F.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2016-03
- Volume
- 115
- Issue
- 02
- Pages
- 368-381
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2160030871
- Cited by
- 75
- References
- 6
- FWCI
- 7.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Edoxaban: Impact on routine and specific coagulation assays: A practical laboratory guide. https://app.cochat.ai/papers/10.1160/th15-05-0415
- The paper
- Chatelain, B., Chatelain, C., Douxfils, J., Dogné, J.-M., & Mullier, F. (2016). Edoxaban: Impact on routine and specific coagulation assays: A practical laboratory guide. Thrombosis and Haemostasis. https://doi.org/10.1160/th15-05-0415
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.